{"id":"NCT03257267","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study of Cemiplimab in Adults With Cervical Cancer","officialTitle":"An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-05","primaryCompletion":"2021-03-15","completion":"2023-04-20","firstPosted":"2017-08-22","resultsPosted":"2022-04-06","lastUpdate":"2025-04-08"},"enrollment":608,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Squamous Cell Carcinoma (SCC)","Recurrent or Metastatic, Platinum-refractory Cervical Cancer"],"interventions":[{"type":"DRUG","name":"Cemiplimab","otherNames":["REGN2810","Libtayo"]},{"type":"DRUG","name":"Investigator Choice (IC) Chemotherapy","otherNames":[]}],"arms":[{"label":"Experimental Therapy","type":"EXPERIMENTAL"},{"label":"Control Therapy","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic cervical cancer who have histology of squamous cell carcinoma (SCC) and who have any eligible histology treated with either cemiplimab or investigator's choice (IC) chemotherapy.\n\nThe secondary objectives performed among SCC patients and among all eligible histologies (SCC and adenocarcinoma/adenosquamous carcinoma (AC) are:\n\n* To compare progression-free survival (PFS) of cemiplimab versus IC chemotherapy\n* To compare objective response rate (ORR) (partial response \\[PR\\] + complete response \\[CR\\]) of cemiplimab versus IC chemotherapy per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* To compare the duration of response (DOR) of cemiplimab versus IC chemotherapy\n* To compare the safety profiles of cemiplimab versus IC chemotherapy by describing adverse events (AE)\n* To compare quality of life (QOL) for patients treated with cemiplimab versus IC chemotherapy using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From first dose up to 90 following last dose (~42 months)","effectByArm":[{"arm":"Cemiplimab","deltaMin":11.7,"sd":null},{"arm":"Investigator Choice (IC) Chemotherapy","deltaMin":8.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.00001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":105,"countries":["United States","Australia","Belgium","Brazil","Canada","Greece","Italy","Japan","Poland","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["35922251","35139273"],"seeAlso":["https://www.trialsummaries.com/"]},"adverseEventsSummary":{"seriousAny":{"events":100,"n":300},"commonTop":["Anaemia","Nausea","Vomiting","Constipation","Pyrexia"]}}